Custom Antibody Market Size

Custom Antibody Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The custom antibody market is expected to reach $ 0.15 billion in 2024, and $ 0.30 billion by 2032. The average annual growth rate for the forecast period is 8.72%. The main driving force for the market is the growing demand for individualized medicine, the development of biotechnology, and the increase in the prevalence of chronic diseases. The need for custom antibodies is increasing, as scientists and medical personnel are looking for more targeted therapies. Also driving the market are the technological developments in the field of antibody engineering and high-throughput screening. Abcam, Thermo Fisher Scientific, and GenScript are leading the way in this development. Recent collaborations between companies to develop new therapies based on custom antibodies illustrate the industry’s commitment to advancing research and improving patient outcomes. The market for custom antibodies is set to continue growing, as a result of these dynamic trends and strategic developments.

Regional Market Size

Regional Deep Dive

The custom-made antibody market is growing at a rapid pace, owing to the rapid developments in biotechnology, an increasing number of research activities, and a rising demand for individualized medicine. North America is characterized by a strong presence of biotechnology companies and research institutions, while Europe is characterized by a strong regulatory framework that supports innovation. Asia-Pacific is quickly becoming a hub for the production of custom-made antibodies, with increasing investments in the health and research sectors. The Middle East and Africa (MEA) region is gradually catching up with the rest of the world, with increasing efforts to improve health systems. Latin America is beginning to take advantage of the increasing demand for custom-made antibodies in research and diagnostics.

North America

• Funding for research on antibodies has been increased by the National Institutes of Health (NIH). This has resulted in several projects that have improved the development of custom-made antibodies.
• GenScript and Abcam are extending their product ranges and expanding their services, focusing on high-quality custom antibody production to meet the growing demand from the pharmaceutical and academic research industries.
• Regulations such as the one requiring the FDA to focus on personalized medicine encourage the development of custom-made antibodies for specific therapeutic applications.

Europe

• The European Medicines Agency (EMA) has published guidelines that will speed up the approval process for custom-made antibodies and encourage innovation in the biopharmaceutical industry.
• The University of Cambridge and Abcam have established a collaboration that is driving the development of the new generation of antibodies.
• Germany and the UK are at the forefront of this development. The demand for custom-made antibodies is growing as the number of patients requiring these antibodies increases.

Asia-Pacific

• China is now a leading country in the production of recombinant DNA, with companies such as Innovagen and BGI Group investing heavily in R & D.
• In Australia, the government has launched a program to encourage the development of biotechnology, thereby enhancing the prospects for the custom antibody market in that country.
• The rising prevalence of chronic diseases in India is expected to drive the demand for custom antibodies in diagnostics and therapeutics.

MEA

• Among the many investments being made in the field of biotechnology under the UAE’s Vision 2021 initiative is the development of a local industry for the manufacture of bespoke monoclonal antibodies.
• Local universities and international biotech companies have started to cooperate in the field of custom antibody development.
• Regulatory frameworks in countries such as South Africa are evolving to support the growth of the custom-made antibody market. However, there are still some difficulties in terms of the necessary equipment.

Latin America

• In Brazil, the budgets for biotechnology are increasing, which will, in turn, help to expand the local production of monoclonal antibodies.
• The establishment of research consortia, such as the Brazilian Consortium for Antibody Research, is facilitating the development of custom-made antibodies.
• The regulatory authorities in Latin America are beginning to adopt more flexible guidelines for biotechnological products, which may help to facilitate the marketing of custom-made antibodies.

Did You Know?

“Customized antibodies are extremely useful in both scientific and medical research. Some are being developed for use in the treatment of cancer.” — Journal of Immunology Research

Segmental Market Size

Custom Antibody is a dynamic sub-market within the broader biopharmaceutical market, currently experiencing robust growth due to an increasing demand for bespoke medicines and more advanced research applications. The rising prevalence of chronic diseases, which require targeted therapies, and the increasing investment in biotech research, especially in oncology and the immune system, are the key drivers of this growth. Further stimulating the market are regulatory developments that favour the development of biologicals.

Custom antibodies are currently in a mature stage of development, and in the market, the leading companies are mainly Abcam and GenScript. Customized antibodies are mainly used in drug development, diagnosis and treatment. The most representative example is the use of custom-made antibodies in monoclonal antibody therapy for cancer treatment. The current influenza pandemic has brought new opportunities for the development of diagnostics and treatments. CRISPR and advanced proteomics have accelerated the development of this industry and made it possible to develop more precise and more efficient antibodies.

Future Outlook

Customized antibodies will have a significant growth from 2024 to 2032, with a steady CAGR of 8.72%. The main driving force for this growth is the increasing demand for individualized medicine, the progress of biotechnology, and the prevalence of chronic diseases, which require targeted therapy. The number of companies and research institutions that develop customized antibodies will increase further. By 2032, about 25% of all therapeutic antibodies will be custom-made, up from about 15% in 2024.

Antibody phage display and hybridoma are important growth drivers. In addition, the use of artificial intelligence and machine learning in the development of monoclonal antibodies is expected to reduce the time and cost of developing new antibodies and improve the quality of the final product. Monoclonal and bi-specific antibodies are also expected to increase the therapeutic potential of monoclonal antibodies. In general, the custom monoclonal antibody market is expected to evolve significantly, driven by technological development and the growing importance of precision medicine.